Recursion Pharmaceuticals (RXRX) Other Non-Current Liabilities (2024 - 2026)

Recursion Pharmaceuticals (RXRX) has 3 years of Other Non-Current Liabilities data on file, last reported at $2.0 million in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 57.72% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 57.72% YoY) and the FY2025 annual result came in at $2.1 million, down 56.04% from the prior year.
• Other Non-Current Liabilities declined to $2.0 million in Q1 2026, from $2.1 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $4.8 million in Q1 2025 to a low of $1.0 million in Q3 2025.
• A 3-year average of $2.8 million and a median of $2.5 million in 2024 frame the typical range for Other Non-Current Liabilities.
• The widest YoY moves for Other Non-Current Liabilities: up 47.83% in 2025, down 65.69% in 2025.
• Tracing RXRX's Other Non-Current Liabilities over 3 years: stood at $4.7 million in 2024, then plunged by 56.04% to $2.1 million in 2025, then fell by 2.64% to $2.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $2.0 million (Q1 2026), $2.1 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.